gilead.com

Webbplats analys gilead.com

 Genereras på December 14 2022 00:39 AM

Gammal statistik? UPDATERA !

Ställningen är 56/100





SEO Innehåll

Titel

Gilead Sciences, Inc.

Längd : 21

Idealisk, din titel bör innehålla mellan 40 och 70 tecken (mellanslag räknas som tecken). Använd denna gratis verktyg för att räkna ut textlängden.

Beskrivning

Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

Längd : 153

Bra, din metabeskrivning innehåller mellan 90 och 160 tecken.

Nyckelord

Mycket dåligt. Vi har inte lyckats hitta några meta-taggar på din sida. Använd denna meta-tag generator, gratis för att skapa nyckelord.

Og Meta Egenskaper

Bra, din sida drar nytta utav Og.

Egendom Innehåll
title Gilead Sciences, Inc.
description Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
image https://wwwam10.gilead.com/-/media/gilead-corporate/images/og/gilead_logo.jpg

Rubriker

H1 H2 H3 H4 H5 H6
1 7 4 3 1 0
  • [H1] World AIDS Day: Striving Together Toward Equity
  • [H2] Contact
  • [H2] Creating a Better Healthier World
  • [H2] Connecting Breast Cancer Education to Community: Equal Hope
  • [H2] Latinas Contra Cancer Empowers Patients to Advocate for Change
  • [H2] Tatiana Williams Leads the Way with the Transinclusive Group
  • [H2] Social
  • [H2] Headline
  • [H3] Advancing Global Health
  • [H3] Sustainability
  • [H3] Partnerships and Community
  • [H3] Recent Stories
  • [H4] Community
  • [H4] Community
  • [H4] Community
  • [H5] Recent News

Bilder

Vi hittade 16 bilder på denna webbsida.

Bra, de flesta eller alla dina bilder innehåller alt-attribut

Text/HTML Ratio

Ratio : 40%

Idealisk! Den här sidans text till HTML-kod förhållande är mellan 25 och 70 procent.

Flash

Perfekt, inga Flash-innehåll har upptäckts på denna sida.

Iframe

Synd, du har Iframes på webbsidorna vilket innebär att innehållet i en Iframe inte kan indexeras.

URL Rewrite

Bra. Dina adressfält ser bra ut!

Understreck i URLen

Perfekt! Inga understreck upptäcktes i din webbadress.

In-page länkar

Vi hittade totalt 161 länkar inklusive 1 länk(ar) till filer

Anchor Typ Juice
Medicine Questions Externa Passing Juice
Report an Adverse Event Interna Passing Juice
Investors Interna Passing Juice
Contact Interna Passing Juice
Canada Externa Passing Juice
Mexico Interna Passing Juice
USA Interna Passing Juice
Argentina Interna Passing Juice
Brazil Interna Passing Juice
China Mainland Externa Passing Juice
Hong Kong Interna Passing Juice
India Interna Passing Juice
Japan Externa Passing Juice
Korea Externa Passing Juice
Singapore Interna Passing Juice
Taiwan Interna Passing Juice
Israel Externa Passing Juice
Saudi Arabia Interna Passing Juice
Türkiye Interna Passing Juice
United Arab Emirates Interna Passing Juice
South Africa Interna Passing Juice
Australia and New Zealand Interna Passing Juice
Austria Interna Passing Juice
Belgium and Luxembourg Externa Passing Juice
Czech Republic & Slovakia Interna Passing Juice
Denmark Interna Passing Juice
Finland Interna Passing Juice
France Externa Passing Juice
Germany Externa Passing Juice
Greece Interna Passing Juice
Iceland Interna Passing Juice
Ireland Interna Passing Juice
Italy Externa Passing Juice
Netherlands Interna Passing Juice
Norway Interna Passing Juice
Poland & The Baltics Interna Passing Juice
Portugal Interna Passing Juice
Romania Interna Passing Juice
Russia Interna Passing Juice
Spain Externa Passing Juice
Sweden Interna Passing Juice
Switzerland Interna Passing Juice
United Kingdom Externa Passing Juice
Mission and Core Values Interna Passing Juice
Partnerships and Community Interna Passing Juice
Inclusion and Diversity Interna Passing Juice
Corporate Giving Interna Passing Juice
Gilead Foundation Interna Passing Juice
Sustainability Interna Passing Juice
Advancing Global Health Interna Passing Juice
Medication Access Interna Passing Juice
Leadership Interna Passing Juice
How We Operate Interna Passing Juice
Ethics and Code of Conduct Interna Passing Juice
Therapeutic Areas Interna Passing Juice
Medicines Interna Passing Juice
Pipeline Interna Passing Juice
Research Interna Passing Juice
Clinical Trials Externa Passing Juice
Events Interna Passing Juice
Stories Interna Passing Juice
Newsroom Interna Passing Juice
Company Statements Interna Passing Juice
Annual Reports Interna Passing Juice
Careers at Gilead Interna Passing Juice
Our Culture Interna Passing Juice
Meet Our Employees Interna Passing Juice
Inclusion and Diversity in Hiring Interna Passing Juice
Compensation, Benefits and Wellbeing Interna Passing Juice
Our Global Footprint Interna Passing Juice
Early Career Opportunities Interna Passing Juice
Postdoctoral Fellowships Interna Passing Juice
Hiring Events Externa Passing Juice
Talent Community Sign-up Externa Passing Juice
Privacy Statements Interna Passing Juice
Terms Of Use Interna Passing Juice
Social Media Guidelines Interna Passing Juice
EU Data Disclosure Interna Passing Juice
Sitemap Interna Passing Juice
BACK TO MAIN MENU Interna Passing Juice
COMPASS Initiative Interna Passing Juice
HepConnect Interna Passing Juice
HIV Age Positively Interna Passing Juice
Lift Interna Passing Juice
RADIAN Interna Passing Juice
TRANScend Interna Passing Juice
What We Fund Interna Passing Juice
Funding Requests Interna Passing Juice
Zeroing In: Ending the HIV Epidemic Interna Passing Juice
Creating Possible Fund Interna Passing Juice
Our Business Is Sustainable Interna Passing Juice
Performance Interna Passing Juice
Reporting Interna Passing Juice
U.N. Global Compact Interna Passing Juice
U.N. Sustainable Development Goals Interna Passing Juice
COVID-19 Interna Passing Juice
HCV Elimination Interna Passing Juice
U.S. Patient Access Interna Passing Juice
Disaster Product Replacement Interna Passing Juice
Global Access Interna Passing Juice
Authorized Distributors Interna Passing Juice
ESG Goals Interna Passing Juice
Governance Interna Passing Juice
Transparency Interna Passing Juice
Policies Interna Passing Juice
Anti-Bribery and Anti-Corruption Policy Interna Passing Juice
Animal Use and Welfare Policy Interna Passing Juice
Disclosures Interna Passing Juice
Anti-Counterfeiting Interna Passing Juice
Consumer Product Safety Interna Passing Juice
Supplier Information Interna Passing Juice
Political Engagement Interna Passing Juice
Research Scholars Program Interna Passing Juice
Compassionate Use Interna Passing Juice
Investigator-Sponsored Research Interna Passing Juice
Press Releases Interna Passing Juice
Media Inquiries Interna Passing Juice
Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus Interna Passing Juice
Gilead Continues Efforts to Halt the Distribution of Counterfeit HIV Medications and Protect Patient Safety Interna Passing Juice
Veklury® (Remdesivir) Demonstrates Continued In Vitro Antiviral Activity Against Omicron Subvariants, Including BA.4 and BA.5 Interna Passing Juice
Sacituzumab Govitecan-Hziy Trodelvy Elevated to Category 1 Preferred Recommendation in Second-Line Metastatic Triple-Negative Breast Cancer Interna Passing Juice
Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir Interna Passing Juice
Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade Interna Passing Juice
All Magrolimab Studies Re-Opening for Patient Enrollment in the U.S. Interna Passing Juice
Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission Interna Passing Juice
Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products Interna Passing Juice
Gilead to Expand Footprint in Oceanside Interna Passing Juice
Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities Interna Passing Juice
Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare Interna Passing Juice
Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain Interna Passing Juice
Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia Interna Passing Juice
Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression Interna Passing Juice
Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates Interna Passing Juice
Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant Interna Passing Juice
Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir Interna Passing Juice
Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union Interna Passing Juice
Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer Interna Passing Juice
Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees Interna Passing Juice
Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States Interna Passing Juice
Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis Interna Passing Juice
Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B) Interna Passing Juice
Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer Interna Passing Juice
Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19 Interna Passing Juice
Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Interna Passing Juice
Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Interna Passing Juice
Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services Interna Passing Juice
Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD Interna Passing Juice
Gilead Sciences Statement on Recent Events in Washington, D.C. Interna Passing Juice
Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP® Interna Passing Juice
Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines Interna Passing Juice
- Interna Passing Juice
- Interna Passing Juice
Year in Review 2021 Interna Passing Juice
Cookie Statement Interna Passing Juice
Partnership Request Interna Passing Juice
Gilead Sciences Again Named to Dow Jones Sustainability World Index Interna Passing Juice
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response Interna Passing Juice
- Externa Passing Juice
Stories@Gilead Interna Passing Juice
Investor Calls Interna Passing Juice
Modern Slavery Act Statement Interna Passing Juice

SEO Nyckelord

Nyckelord Moln

gilead      remdesivir      sciences      back      community      hiv      statement      menu      main      together     

Nyckelord Konsistens

Nyckelord Innehåll Titel Nyckelord Beskrivning Rubriker
gilead 37
back 16
main 16
menu 16
statement 16

Användbarhet

Url

Domän : gilead.com

Längd : 10

Favikon

Bra, din webbplats har en favicon.

Utskriftbart

Vi kunde inte hitta CSS för utskrifter.

Språk

Bra. Ditt angivna språk är en.

Dublin Core

Denna sida drar inte nytta utav Dublin Core.

Dokument

Doctype

HTML 5

Encoding

Perfekt. Din deklarerade teckenuppsättning är UTF-8.

W3C Validity

Errors : 12

Varningar : 15

E-post Sekretess

Varning! Minst en e-postadress har påträffats i klartext. Använd gratis antispam skydd för att dölja e-post från spammare.

Föråldrad HTML

Bra! Vi har inte hittat några föråldrad HTML taggar i din HTML.

Hastighets Tips

Utmärkt, din webbplats använder inga nästlade tabeller.
Synd, din webbplats använder sig utav inline stilar.
Bra, din webbplats har få CSS-filer.
Synd, din webbplats har för många JS filer (fler än 6 stycken).
Perfekt, din webbplats utnyttjar gzip.

Mobil

Mobiloptimering

Apple Ikon
Meta Viewport Tagg
Flash innehåll

Optimering

XML Sitemap

Saknas

Din webbplats saknar en XML sitemap - detta kan orsaka ett problem.

Eftersom en sitemap listar webbadresser som är tillgängliga för genomsökning och kan innehålla ytterligare information såsom din webbplats senaste uppdatering, antal förändringar och betydelsen av webbadresserna. Detta gör det möjligt för sökmotorer att på ett mer intelligent sätt genomsöka webbplatsen.

Robots.txt

http://gilead.com/robots.txt

Bra, din webbplats har en robots.txt fil.

Analytics

Saknas

Vi hittade inte någon analysverktyg på din webbplats.

Webbanalys program kan mäta besökare på din webbplats. Du bör ha minst ett analysverktyg installerat, men det kan också vara en bra ide att installera två för att dubbelkolla uppgifterna.

PageSpeed Insights

Enhet
Kategorier

Website Review

Website Review är en fri SEO verktyg som hjälper dig att analysera din webbplats